Sex Age at onset (y)
Recovery from AIN
Age at
recovery (y) Associated autoimmunity
M 15,12 yes 15,89 ES (AIN+ thrombocytopenia); DAT pos
F 13,80 yes 14,12 Celiac disease; Autoimmune thyroiditis (anti-TPO pos) F 2 no Autoimmune hepatitis; ES (AIN+ thrombocytopenia); DAT pos
F 7,87 no IDDM; ANA 1:320
M 10,6 no Celiac disease; ES (AIN+ thrombocytopenia); DAT pos
M 10,82 no ES (tri-lineage); ANA 1:160; GH deficiency
F 3,76 no ES (tri-lineage); autoimmune encephalitis
M 13,43 no ES (AIN+ thrombocytopenia); DAT pos
M 4,02 no ES (AIN+ thrombocytopenia); ANA 1:320; arthritis
M 0,5 no ES (AIN + AIHA)
M 17,17 no ES (tri-lineage); ANA 1:160
F 12,42 no ES (tri-lineage); ANA 1:640; SLE
F 13,33 no ES (tri-lineage); ANA 1:160;
F 15,55 no Autoimmune thyroiditis (anti-TPO pos; anti-TG pos) F 13,43 no Autoimmune thyroiditis (anti-TPO pos; anti-TG pos)
F 7,45 no Autoimmune thyroiditis (anti-TG pos)
M 7,49 no Autoimmune thyroiditis (anti-TPO pos)
F 16,47 no Autoimmune thyroiditis (anti-TPO pos; anti-TG pos); ANA 1:1280 M 9,54 no Autoimmune thyroiditis (anti-TG pos); ANA 1:320
F 11,98 no GH deficiency; ANA 1:320
F 7,4 no GH deficiency; ANA 1:320
M 12,49 no IDDM
F 0,63 no ANA 1:160; arthralgia; ASMA pos; anti-GAD pos
F 7,2 no ANA 1:1280; arthralgia
F 2,65 no ANA 1:320; arthralgia; anti-DNA pos
F 7,1 no ANA 1:320; arthralgia
Table 2. Characteristics of s-AIN patients
ES: Evans syndrome; pos: positivity; AIN: autoimmune neutropenia; DAT: direct antiglobulin test; anti-TPO: anti-thyroid peroxidase antibodies; IDDM: insulin-dependent diabetes mellitus; ANA: antinuclear antibodies; GH: growth hormone; AIHA: autoimmune hemolytic anemia; TG: thyroglobulin antibodies; ASMA: anti-smooth muscle antibodies; anti-GAD: anti-glutamic acid decarboxylase antibodies; anti-DNA: anti-double stranded DNA antibodies; SLE: Systemic lupus erythematosus.
